Vanguard Group Inc Cytokinetics Inc Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 11,915,821 shares of CYTK stock, worth $515 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,915,821
Previous 11,761,605
1.31%
Holding current value
$515 Million
Previous $621 Million
9.74%
% of portfolio
0.01%
Previous 0.01%
Shares
15 transactions
Others Institutions Holding CYTK
# of Institutions
397Shares Held
114MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$634 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$464 Million0.31% of portfolio
-
State Street Corp Boston, MA6.17MShares$266 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.84MShares$123 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.72MShares$118 Million2.09% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.07B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...